Tissue-based diagnostic tests are performed for screening, diagnosing, and monitoring the response of cancer patients to therapy. Tissue-based diagnostic tests are used in breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and other diseases (bone cancer, cervical cancer, colon cancer, cervix cancer, gallbladder carcinoma, skin cancer, HBV, Epstein-Barr virus, hepatitis, and muscular dystrophies). Diagnostic tests are carried out to identify a medical condition in its early stage so as to establish the correct course of treatment. Tissue diagnostic tests are also carried out to determine the course of recovery and response to the treatment."

Visionary leaders are the leading market players in terms of new developments such as product launches, innovative technologies, and the adoption of growth strategies. These players have a broad product offering that caters to most of the regions globally. Visionary leaders primarily focus on acquiring the leading market position through their strong financial capabilities and their well-established brand equity.

Dynamic Differentiators are established players with very strong business strategies. However, they have a weaker product portfolio compared to the visionary leaders. They generally focus only on a specific type of technology related to the product.

Innovators in the competitive leadership mapping are vendors that have demonstrated substantial product innovations as compared to their competitors. The companies have focused on product portfolios. However, they do not have very strong growth strategies for their overall business, when compared with the visionary leaders.

Emerging companies have niche product and service offerings. Their business strategies are not as strong as that of the established vendors. The emerging vendors include the new entrants in the market, emerging in terms of product portfolio and geographic reach, and require time to gain significant traction in the market.